UBS Group’s Novo Nordisk A/S (B Shares) ADRhedged NVOH Stock Holding History

UBS Group’s Portfolio NVOH Stock Details NVOH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10	Closed	-$206	–	11345
2026 Q1	$206	Buy	+10	New	+$256	﹤0.01%	10029
2025 Q4	–	Sell	-81	Closed	-$2.44K	–	11435
2025 Q3	$2.44K	Sell	81 -254	-76%	-$8.05K	﹤0.01%	9173
2025 Q2	$12.2K	Hold	335	–	–	﹤0.01%	8744
2025 Q1	$13.4K	Buy	+335	New	+$16.1K	﹤0.01%	8462

UBS Group's NVOH Position: Q2 2026 in Review

UBS Group sold out of Novo Nordisk A/S (B Shares) ADRhedged (NVOH) in Q2 2026, closing a stake of 10 shares — an estimated $206 sold.

UBS Group first reported a position in NVOH in Q1 2025 and held it in 4 quarters. The position peaked at $13.4K in Q1 2025. 0 funds tracked by Wall St. Rank hold NVOH as of Q2 2026.

UBS Group reported no remaining Novo Nordisk A/S (B Shares) ADRhedged position as of Q2 2026 after selling out during the quarter.
UBS Group sold 10 Novo Nordisk A/S (B Shares) ADRhedged shares in Q2 2026, an estimated $206.
UBS Group first reported a position in Novo Nordisk A/S (B Shares) ADRhedged in Q1 2025 and held it in 4 quarters.
UBS Group's Novo Nordisk A/S (B Shares) ADRhedged position peaked at $13.4K in Q1 2025.
0 funds tracked by Wall St. Rank held Novo Nordisk A/S (B Shares) ADRhedged as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.